Brent Sabatini Biography and Net Worth

CAO of Vir Biotechnology

Brent Sabatini is the CAO of Vir Biotechnology. They are 52 years old.

What is Brent Sabatini's net worth?: The estimated net worth of Brent Sabatini is at least $560.83 thousand as of March 23rd, 2026. Sabatini owns 61,902 shares of Vir Biotechnology stock worth more than $560,832 as of April 5th. This net worth estimate does not reflect any other investments that Sabatini may own. Learn More about Brent Sabatini's net worth.
How do I contact Brent Sabatini?: The corporate mailing address for Sabatini and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Brent Sabatini's contact information.
Has Brent Sabatini been buying or selling shares of Vir Biotechnology?: Brent Sabatini has not been actively trading shares of Vir Biotechnology during the last quarter. Most recently, Brent Sabatini sold 7,711 shares of the business's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $9.12, for a transaction totalling $70,324.32. Following the completion of the sale, the chief accounting officer now directly owns 61,902 shares of the company's stock, valued at $564,546.24. Learn More on Brent Sabatini's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Marianne De Backer (CEO & Director), Vanina de Verneuil (EVP, General Counsel and Corporate Secretary), Mark Eisner (Executive Vice President and Chief Medical Officer), Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Jason O'Byrne (Executive Vice President and Chief Financial Officer), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Brent Sabatini (CAO), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 52 times. They sold a total of 3,318,505 shares worth more than $20,488,792.06. The most recent insider tranaction occured on April, 1st when Director Vicki L Sato sold 22,000 shares worth more than $199,540.00. Insiders at Vir Biotechnology own 16.0% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 4/1/2026.

Brent Sabatini Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/23/2026	Sell	7,711	$9.12	$70,324.32	61,902
2/24/2026	Sell	1,430	$9.53	$13,627.90	69,613
2/23/2026	Sell	1,829	$7.45	$13,626.05	71,043
2/13/2026	Sell	1,530	$7.79	$11,918.70	47,872
2/13/2025	Sell	1,562	$9.15	$14,292.30	28,189

Brent Sabatini Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $9.06

$8.65

$9.40

50 Day Range

MA: $8.52

$6.92

$10.00

2 Week Range

Now: $9.06

$4.16

$10.94

Volume

1,727,127 shs

Average Volume

2,557,070 shs

Market Capitalization

$1.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66